Daxor Corporation DXR 深 沪
已收盘 02-06 16:00:00 美东时间
12.345
+0.085
+0.69%
华盛通- 最 高12.5949
- 今 开12.345
- 成交量 1269股
- 最 低 12.345
- 昨 收 12.26
- 总市值 7193.71万
- 52周最高 14.7578
- 市盈率 静 111.42
- 换手率 0.02%
- 52周最低 7.00
- 委 比 -81.55%
- 总股本 582.72万
- 历史最高 24.076
- 量 比 0.32
- 振 幅 2.04%
- 历史最低 0.00
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Daxor Releases Updated Investor Presentation to Public Markets
Daxor ( ($DXR) ) has shared an announcement. Daxor Corporation disclosed that i...
01-23 19:34
Daxor Corporation Announces $9 Million Registered Direct Offering
Daxor Corporation announced the sale of 765,958 shares of common stock at $11.75 per share, expected to generate approximately $9 million in gross proceeds. The offering, facilitated by Lake Street Capital Markets as the exclusive placement agent, is set to close on January 26, 2026, subject to customary conditions. Proceeds will be used for general corporate purposes, including working capital. The registration statement was declared effective b...
01-23 13:00
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Daxor Corporation expanded its BVA platform into three new facilities, signaling accelerating market adoption. The company's dual-solution strategy—on-site BVA analyzer and ezBVA Lab Service—aims to improve patient outcomes and reduce healthcare costs. Recent wins include high-volume cardiology and heart failure diagnostics adoption by leading healthcare institutions. CEO Michael Feldschuh highlighted this as a pivotal moment, emphasizing the dua...
2025-11-25 13:00
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
Daxor Corporation's CEO, Michael Feldschuh, will participate in the Maxim Growth Summit on October 22-23, 2025, in New York City, engaging with institutional investors and senior Maxim analysts. The invitation-only event, hosted by Maxim Group LLC, features 40 selected healthcare companies and high-profile speakers like Larry Kudlow and Christopher Ruddy. For more details, visit www.maximgrp.com/2025-growth-summit.
2025-10-21 12:00
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
Daxor Corporation, a leader in blood volume measurement technology, will exhibit its next-generation BVA diagnostic system at the MedAxiom Cardiovascular Transforum Fall’25 Conference in Austin, TX. The company aims to showcase how this innovation addresses challenges like hospital readmissions and resource optimization. Daxor, with over 50 years of experience, specializes in precise blood volume analysis, improving patient outcomes and healthcar...
2025-10-15 12:00
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
Daxor Corporation announced the successful launch of its FDA-cleared next-generation BVA analyzer, validated by three studies showing significant reductions in hospital readmissions and improved survival rates across high-cost heart failure segments. The BVA technology demonstrated zero unplanned hospital admissions for optimally managed heart failure patients, improved 30-day and 1-year survival rates for LVAD implantation patients, and helped d...
2025-09-30 12:00
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
<p align="justify"> Daxor Corporation, the global leader in blood volume measurement technology, announced at the Heart Failure Society of America (HFSA) Annual Scientific Meeting that it will exhibit its newly FDA-cleared next-generation blood volume analyzer (BVA), marking a new era in fluid management. The analyzer is three times faster than its predecessor, requires 50% less blood, and delivers over 95% accuracy. The company will also present...
2025-09-23 12:00
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
A new pilot study published in the Journal of Critical Care highlights frequent inaccuracies in clinical fluid level assessments for critically ill patients with sepsis and COVID-19, often leading to misclassification of fluid status. The study, co-authored by Dr. Jan Bakker and utilizing Daxor's FDA-approved BVA-100™ Analyzer, found that 48% of COVID-19 patients were incorrectly diagnosed as hypervolemic when they were hypovolemic. The research ...
2025-09-04 12:00
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Oak Ridge, TN, Sept. 03, 2025 - Daxor Corporation (NASDAQ: DXR), a global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York City. The presentation will be available on-demand starting September 5 at 7:00 a.m. ET. Investors can register for the conference at https://hcwevents.com/annualco...
2025-09-03 12:00
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Daxor Corporation reported a 73% increase in revenue and a $0.40 per share rise in NAV during the first half of 2025. The company secured FDA clearance for its new rapid, lightweight Blood Volume Analysis (BVA) system, showcasing significant advancements in product innovation and market adoption. Clinical validation strengthened with key studies, including improved survival rates for heart failure patients and critical findings in COVID-19 and se...
2025-09-02 12:00
